Danaher Corp said on Tuesday it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt, to strengthen its diagnostics unit.
Danaher will pay Cepheid $53 per share in cash, a premium of 54 percent to its Friday close of $34.42, and the transaction is expected to close in the fourth quarter.
02:18 Report: Royals, Cubs close to trading Wade Davis for Jorge Soler11
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle21
14:45 Spain raises taxes to try to meet EU deficit target16